Tag: Nektar Therapeutics (NKTR)

The Bizarre Market

The Bizarre Market

The Week in Review #41 We Are Still Witnessing … The bizarre market performance that started in early 2019: In the past couple of months the great enthusiasm and response of the market to the undeniably strong economic indicators and the lowest unemployment figures turned, for mysterious reasons, to a perturbed-looking volatile market beast. The biotech stocks have given back most of their deserved gains …
Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company unveiled that some of the patients treated in . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Nektar’s Q2 Press Release

Nektar’s Q2 Press Release

Nektar’s Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December 31, 2018.  “Nektar is making good progress advancing our multiple programs in immuno-oncology, immunology, and pain,” said Howard W. Robin, President, and CEO of Nektar. “With our partner Bristol-Myers Squibb, …
Unveiled Good News About Prohost Picked Biotech Stocks

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second eye on the market performance, its volatility and the possible reasons it sinks every other day, or every other week, in calmer days during a …
The Nektar Good News Cannot be Hidden Any Longer

The Nektar Good News Cannot be Hidden Any Longer

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. Its current pipeline is filled with promising products. Today we learned that the U.S. FDA granted Nektar’s and Bristol-Myers Squibb’s . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

Nektar Announced Results for NKTR-358  During an oral session at the Annual European Congress of Rheumatology (EULAR) 2019, in Madrid, Nektar Therapeutics (NKTR) announced results of the first-in-human Phase 1a study evaluating single-ascending doses of NKTR-358 for the treatment of autoimmune and other chronic inflammatory conditions.  The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
The ASCO 2019 Special Edition

The ASCO 2019 Special Edition

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed victim of the instigated and irrelevant fear against investing in the stock market is the market itself. Indeed, baseless fear campaigns frighten positive investors while encouraging short-selling investors to maximize their selling which intensifies the markets volatility. We have been experiencing this phenomenon since the beginning of 2019. Market …
From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the improvements in the immune-oncology approaches. The Oncologists Want to Hear About: Up-to-date information from clinical trials on immunotherapies in order to practice the safest and …
Recent News from Incyte, Merck and Nektar

Recent News from Incyte, Merck and Nektar

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label expansion of the Incyte (INCY) product Jakafi (ruxolitinib) for graft-versus-host disease (GVHD) in people 12 years and older. The FDA previously granted Jakafi Breakthrough therapy designation and orphan drug status for acute GVHD. GVHD is a condition that might occur after an . . . This content is for paid subscribers. Please …
Nektar presentation today at the ASCO genitourinary cancers symposium

Nektar presentation today at the ASCO genitourinary cancers symposium

Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at Moscone West in San Francisco, CA, Nektar (NKTR) will present preliminary efficacy, safety and immune monitoring data from the ongoing metastatic urothelial carcinoma (mUC) patient cohort in the PIVOT-02 study evaluating NKTR-214 in combination with Bristol-Myers immunotherapy product OPDIVO (nivolumab). NKTR-214 is a CD122-biased agonist designed to provide sustained …
Now You See It, Now You Don’t

Now You See It, Now You Don’t

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be displayed or concealed depending on the news announcers’ or bloggers’ self-interests. The following contains cases of deliberate or unintentional omission of facts that led to the decline of fundamentally sound biotech and biopharmaceutical firms in bullish market during the departed trading week . . . This content is for paid subscribers. Please …
End of the Year Decisions Part 2

End of the Year Decisions Part 2

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected volatility in the stock market, we carefully reassessed each and very stock we picked for the Prohost Portfolio. Consequently, we had to change many of our 2019 targets in all 7 tables which represents the whole portfolio of companies we believe are offering lucrative investment opportunities. On January 3, …
Improving on immunotherapy and preventing one of its serious side effects

Improving on immunotherapy and preventing one of its serious side effects

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. Removal of glutamine leads to a substantial reduction in cell growth or induces cell death in certain types of cancer cells, indicating that these cells are dependent on, or "addiected" to, glutamine. Normal cells do not depend much on glutamine . . . This content is for paid subscribers. …
Excellent news about little known products and Nektar Therapeutics

Excellent news about little known products and Nektar Therapeutics

The Week in Review, which we will post soon, is going to provide news that cancer patients, their parents, their oncologists and investors are anxiously waiting to hear.   The news is about studies with products demonstrating huge improvements in immunotherapy efficacy in addition to preventing checkpoint inhibitors such as: Opdivo, Keytruda and others, from causing adverse effects, including autoimmune reactions that are serious and …
What is looking good in the aggressive portfolio

What is looking good in the aggressive portfolio

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO  - The aggressive portfolio hosts biotech firms with solid scientific fundamentals and prominent scientists whose stocks have plummeted following some setbacks. A setback could be a failure of an investigational product to meet the endpoints of its clinical trial or that the small biotech firm has taken long to achieve its goals . . . This content …
New stock selection and re-evaluation

New stock selection and re-evaluation

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The firms we tackled in the past issue comprised: 1. Firms we liked and added to our portfolio. 2. Firms we posted their good news, but did not select... 
About Nektar’s product NKTR- 214 at ASCO

About Nektar’s product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was viewed as positive by many analysts and investor until a sell-side negative article led to an unwarranted giant selloff of the stock. Last Week Nektar Stock gained $10 dollars over news that the firm has already submitted a New Drug Application (NDA) to the FDA for NKTR-181, which is …
Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

Nektar and Takeda Explore Immunotherapy Combinations for Multiple Cancers. Sangamo Is Financing Through Public Offering

NEKTAR Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY) are collaborating to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential combination for multiple cancer settings.  NKTR-214 is an experimental immuno-stimulatory recognized to expand specific cancer-fighting T cells and natural killer (NK) cells directly into the cancer micro-environment. The drug also increases the expression of PD-1 on these immune cells. TAK-659 inhibits both spleen tyrosine kinase (SYK), which is involved in . . . …
Real Breakthroughs

Real Breakthroughs

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary Promises In  the  NEWS - THE POWER OF CHECKPOINT INHIBITOR IMMUNOTHERAPY WOW It is about the checkpoint inhibitors immunotherapy, which is bringing to the world of cancer a stunning revelation of a combination treatment offering an almost cure for a lung cancer...